In Vitro-in Vivo Correlation for Complex Non-oral Drug Products: Where Do We Stand?

Overview

Journal J Control Release

Specialty Pharmacology

Date 2015 Oct 1

PMID 26419305

Citations 30

Authors

Jie Shen

Diane J Burgess

Affiliations

Soon will be listed here.

Abstract

In vitro–in vivo correlation (IVIVC) is a predictive mathematical model describing the relationship between an in vitro property and a relevant in vivo response of drug products. Since the U.S. Food and Drug Administration (FDA) published a regulatory guidance on the development, evaluation, and applications of IVIVC for extended release (ER) oral dosage forms in 1997, IVIVC has been one of the most important issues in the field of pharmaceutics. However, even with the aid of the FDA IVIVC Guidance, only very limited Abbreviated New Drug Application (ANDA) submission for ER oral drug products included adequate IVIVC data to enable the completion of bioequivalence (BE) review within first review cycle. Establishing an IVIVC for non-oral dosage forms has remained extremely challenging due to their complex nature and the lack of in vitro release methods that are capable of mimicking in vivo drug release conditions. This review presents a general overview of recent advances in the development of IVIVC for complex non-oral dosage forms (such as parenteral polymeric microspheres/implants, and transdermal formulations), and briefly summarizes the knowledge gained over the past two decades. Lastly this review discusses possible directions for future development of IVIVC for complex non-oral dosage forms.

Citing Articles

Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies.

Nakmode D, Singh B, Abdella S, Song Y, Garg S Drug Deliv Transl Res. 2024; 15(4):1156-1180.

PMID: 39661312 PMC: 11870889. DOI: 10.1007/s13346-024-01747-y.

In vitro-in vivo correlation (IVIVC) development for long-acting injectable drug products based on poly(lactide-co-glycolide).

Wang Y, Otte A, Park H, Park K J Control Release. 2024; 377:186-196.

PMID: 39542257 PMC: 11663134. DOI: 10.1016/j.jconrel.2024.11.021.

Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions.

Anchordoquy T, Artzi N, Balyasnikova I, Barenholz Y, La-Beck N, Brenner J ACS Nano. 2024; 18(22):13983-13999.

PMID: 38767983 PMC: 11214758. DOI: 10.1021/acsnano.4c00182.

Sustained release local anesthetics for pain management: relevance and formulation approaches.

Getachew M, Tesfaye H, Yihunie W, Ayenew T, Alemu S, Dagnew E Front Pain Res (Lausanne). 2024; 5:1383461.

PMID: 38645568 PMC: 11026556. DOI: 10.3389/fpain.2024.1383461.

An Ultrasoft and Flexible PDMS-Based Balloon-Type Implantable Device for Controlled Drug Delivery.

Muhammad T, Park B, Intisar A, Kim M, Park J, Kim S Biomater Res. 2024; 28:0012.

PMID: 38560578 PMC: 10981933. DOI: 10.34133/bmr.0012.

References

Cordoba-Diaz M, Nova M, Elorza B, Cordoba-Diaz D, Chantres J . Validation protocol of an automated in-line flow-through diffusion equipment for in vitro permeation studies. J Control Release. 2000; 69(3):357-67. DOI: 10.1016/s0168-3659(00)00306-0. View

Negrin C, Delgado A, Llabres M, Evora C . In vivo-in vitro study of biodegradable methadone delivery systems. Biomaterials. 2001; 22(6):563-70. DOI: 10.1016/s0142-9612(00)00214-3. View

Uppoor V . Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Control Release. 2001; 72(1-3):127-32. DOI: 10.1016/s0168-3659(01)00268-1. View

Jiang G, Woo B, Kang F, Singh J, DeLuca P . Assessment of protein release kinetics, stability and protein polymer interaction of lysozyme encapsulated poly(D,L-lactide-co-glycolide) microspheres. J Control Release. 2002; 79(1-3):137-45. DOI: 10.1016/s0168-3659(01)00533-8. View

Faisant N, Siepmann J, Benoit J . PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. Eur J Pharm Sci. 2002; 15(4):355-66. DOI: 10.1016/s0928-0987(02)00023-4. View

Shabbits J, Chiu G, Mayer L . Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. J Control Release. 2002; 84(3):161-70. DOI: 10.1016/s0168-3659(02)00294-8. View

Nelson E . Solution rate of theophylline salts and effects from oral administration. J Am Pharm Assoc Am Pharm Assoc. 1957; 46(10):607-14. DOI: 10.1002/jps.3030461012. View

Schliecker G, Schmidt C, Fuchs S, Ehinger A, Sandow J, Kissel T . In vitro and in vivo correlation of buserelin release from biodegradable implants using statistical moment analysis. J Control Release. 2003; 94(1):25-37. DOI: 10.1016/j.jconrel.2003.09.003. View

Prausnitz M, Mitragotri S, Langer R . Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov. 2004; 3(2):115-24. DOI: 10.1038/nrd1304. View

10.

Blanco-Prieto M, Campanero M, Besseghir K, Heimgatner F, Gander B . Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres. J Control Release. 2004; 96(3):437-48. DOI: 10.1016/j.jconrel.2004.02.015. View

11.

Burgess D, Crommelin D, S Hussain A, Chen M . Assuring quality and performance of sustained and controlled released parenterals. Eur J Pharm Sci. 2004; 21(5):679-90. DOI: 10.1016/j.ejps.2004.03.001. View

12.

Medlicott N, Waldron N, Foster T . Sustained release veterinary parenteral products. Adv Drug Deliv Rev. 2004; 56(10):1345-65. DOI: 10.1016/j.addr.2004.02.005. View

13.

Chaturvedula A, Joshi D, Anderson C, Morris R, Sembrowich W, Banga A . Dermal, subdermal, and systemic concentrations of granisetron by iontophoretic delivery. Pharm Res. 2005; 22(8):1313-9. DOI: 10.1007/s11095-005-5335-z. View

14.

Iyer S, Barr W, Karnes H . Profiling in vitro drug release from subcutaneous implants: a review of current status and potential implications on drug product development. Biopharm Drug Dispos. 2006; 27(4):157-70. DOI: 10.1002/bdd.493. View

15.

Zolnik B, Leary P, Burgess D . Elevated temperature accelerated release testing of PLGA microspheres. J Control Release. 2006; 112(3):293-300. DOI: 10.1016/j.jconrel.2006.02.015. View

16.

Chu D, Fu X, Liu W, Liu K, Li Y . Pharmacokinetics and in vitro and in vivo correlation of huperzine A loaded poly(lactic-co-glycolic acid) microspheres in dogs. Int J Pharm. 2006; 325(1-2):116-23. DOI: 10.1016/j.ijpharm.2006.06.032. View

17.

Emami J . In vitro - in vivo correlation: from theory to applications. J Pharm Pharm Sci. 2006; 9(2):169-89. View

18.

Prescott J, Krieger T, Lipka S, Staples M . Dosage form development, in vitro release kinetics, and in vitro-in vivo correlation for leuprolide released from an implantable multi-reservoir array. Pharm Res. 2007; 24(7):1252-61. DOI: 10.1007/s11095-007-9243-2. View

19.

Vlugt-Wensink K, de Vrueh R, Gresnigt M, Hoogerbrugge C, van Buul-Offers S, de Leede L . Preclinical and clinical in vitro in vivo correlation of an hGH dextran microsphere formulation. Pharm Res. 2007; 24(12):2239-48. PMC: 2063566. DOI: 10.1007/s11095-007-9433-y. View

20.

Zolnik B, Burgess D . Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. J Control Release. 2008; 127(2):137-45. DOI: 10.1016/j.jconrel.2008.01.004. View